DNA
Price
$7.29
Change
+$0.51 (+7.52%)
Updated
Apr 10, 04:59 PM (EDT)
Capitalization
423.65M
PRME
Price
$1.17
Change
-$0.08 (-6.40%)
Updated
Apr 10, 04:59 PM (EDT)
Capitalization
153.46M
29 days until earnings call
Ad is loading...

DNA vs PRME

Header iconDNA vs PRME Comparison
Open Charts DNA vs PRMEBanner chart's image
Ginkgo Bioworks Holdings
Price$7.29
Change+$0.51 (+7.52%)
Volume$13.62K
Capitalization423.65M
Prime Medicine
Price$1.17
Change-$0.08 (-6.40%)
Volume$17.73K
Capitalization153.46M
DNA vs PRME Comparison Chart
Loading...
DNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PRME
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
DNA vs. PRME commentary
Apr 11, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DNA is a StrongBuy and PRME is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 11, 2025
Stock price -- (DNA: $6.78 vs. PRME: $1.25)
Brand notoriety: DNA and PRME are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: DNA: 92% vs. PRME: 193%
Market capitalization -- DNA: $423.65M vs. PRME: $153.46M
DNA [@Biotechnology] is valued at $423.65M. PRME’s [@Biotechnology] market capitalization is $153.46M. The market cap for tickers in the [@Biotechnology] industry ranges from $263.69B to $0. The average market capitalization across the [@Biotechnology] industry is $2.01B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DNA’s FA Score shows that 1 FA rating(s) are green whilePRME’s FA Score has 0 green FA rating(s).

  • DNA’s FA Score: 1 green, 4 red.
  • PRME’s FA Score: 0 green, 5 red.
According to our system of comparison, both DNA and PRME are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DNA’s TA Score shows that 6 TA indicator(s) are bullish while PRME’s TA Score has 4 bullish TA indicator(s).

  • DNA’s TA Score: 6 bullish, 3 bearish.
  • PRME’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, DNA is a better buy in the short-term than PRME.

Price Growth

DNA (@Biotechnology) experienced а +13.76% price change this week, while PRME (@Biotechnology) price change was -30.17% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -7.53%. For the same industry, the average monthly price growth was -18.05%, and the average quarterly price growth was -19.90%.

Reported Earning Dates

DNA is expected to report earnings on Nov 11, 2024.

PRME is expected to report earnings on May 09, 2025.

Industries' Descriptions

@Biotechnology (-7.53% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
DNA($424M) has a higher market cap than PRME($153M). DNA YTD gains are higher at: -30.957 vs. PRME (-57.192). PRME has higher annual earnings (EBITDA): -196.34M vs. DNA (-484.39M). DNA has more cash in the bank: 562M vs. PRME (190M). PRME has less debt than DNA: PRME (40.8M) vs DNA (468M). DNA has higher revenues than PRME: DNA (227M) vs PRME (2.98M).
DNAPRMEDNA / PRME
Capitalization424M153M277%
EBITDA-484.39M-196.34M247%
Gain YTD-30.957-57.19254%
P/E RatioN/AN/A-
Revenue227M2.98M7,610%
Total Cash562M190M296%
Total Debt468M40.8M1,147%
FUNDAMENTALS RATINGS
PRME: Fundamental Ratings
PRME
OUTLOOK RATING
1..100
77
VALUATION
overvalued / fair valued / undervalued
1..100
39
Fair valued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
96
PRICE GROWTH RATING
1..100
97
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
51

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
DNAPRME
RSI
ODDS (%)
Bullish Trend 2 days ago
88%
Bullish Trend 2 days ago
88%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
79%
Momentum
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bullish Trend 2 days ago
84%
Bearish Trend 2 days ago
87%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
77%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
87%
Advances
ODDS (%)
Bullish Trend 18 days ago
81%
Bullish Trend 22 days ago
78%
Declines
ODDS (%)
Bearish Trend 7 days ago
86%
Bearish Trend 3 days ago
89%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
70%
Aroon
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Ad is loading...
DNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PRME
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
VEUAX30.34N/A
N/A
JPMorgan Europe Dynamic A
FIGCX17.12N/A
N/A
Fidelity Advisor International Growth C
JSPJX16.62N/A
N/A
Jackson Square Large-Cap Growth Inv
GEBNX9.03N/A
N/A
Goldman Sachs ESG Em Mkts Eq Inv
PGHAX60.30N/A
N/A
Putnam Global Health Care R6

PRME and

Correlation & Price change

A.I.dvisor indicates that over the last year, PRME has been loosely correlated with CRSP. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if PRME jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PRME
1D Price
Change %
PRME100%
+8.70%
CRSP - PRME
63%
Loosely correlated
+11.58%
BEAM - PRME
57%
Loosely correlated
+12.59%
RXRX - PRME
57%
Loosely correlated
+17.13%
NTLA - PRME
55%
Loosely correlated
+12.74%
ABCL - PRME
53%
Loosely correlated
+11.92%
More